PhRMA PRESENTS THE 2013
Research & Hope Awards

Celebrating Progress,
Building on Research,
Providing Hope
The Pharmaceutical Research & Manufacturers of America, along with the American Cancer Society Cancer Action Network (ACS CAN), American Nurses Association, American Osteopathic Association and National Association of School Nurses, are pleased to honor individuals and organizations for their significant contributions to advancing vaccine research and immunization. Tonight, we proudly recognize outstanding researchers, health care providers, and public health advocates.

2013 Research & Hope Awards are presented this evening in the following categories:

1. **The Research & Hope Award for Academic or Public Research in Vaccine Development**
   Presented to individuals or a team from academic or government institutions for outstanding research in the area of vaccine development.

2. **The Research & Hope Award for Biopharmaceutical Industry Research in Vaccine Development**
   Presented to individuals or a team from a biopharmaceutical company for outstanding research in the area of vaccine development.

3. **The Research & Hope Award for Patient and Community Health**
   Presented to individuals or an organization that has had a significant impact educating parents, health care providers or students about the importance of childhood immunizations and facilitating increased vaccinations in their community.

This year's honorees and their inspiring work are presented on the following pages. We commend and congratulate them and celebrate their outstanding contributions to improving public health in the United States and throughout the world.
Wednesday, September 11, 2013 - 6 P.M.

2013 RESEARCH & HOPE AWARDS DINNER
The Newseum | 555 Pennsylvania Avenue N.W. | Washington, DC

RECEPTION

DINNER SEATING
Welcome Remarks from WUSA9 Anchor and Health Correspondent Anita Brikman
Remarks from PhRMA President & CEO John Castellani
Remarks from PhRMA Chairman Bob Hugin
Dinner Service
Keynote Address:
Tom Frieden, MD, MPH, Director, Centers for Disease Control & Prevention

AWARDS PRESENTATION

Meet our speaker

Thomas R. Frieden, MD, MPH
Director, Centers for Disease Control and Prevention

Tom Frieden, MD, MPH, who has been Director of the Centers for Disease Control and Prevention (CDC) since June 2009, has controlled both infectious and chronic diseases in this country and globally. From 1992-1996, he led New York City’s program that controlled tuberculosis and reduced multidrug-resistant cases by 80 percent. Dr. Frieden then worked in India for five years helping build a tuberculosis control program that has saved nearly 3 million lives.

As Commissioner of the New York City Health Department (2002-2009), Dr. Frieden led programs that reduced illness and death and increased life expectancy substantially, including programs that reduced adult and teen smoking dramatically and eliminated artificial trans-fats from restaurants. The Department eliminated racial/ethnic disparities in colon cancer screening and began the country’s largest community-based electronic health records project.

As CDC Director, Dr. Frieden has intensified CDC’s 24-7 work to save lives and protect people, including through more effective response to outbreaks and other health threats at the local, state, federal, and global levels. New programs have prevented infections from food and health care, helped Americans quit smoking, reduced childhood obesity, saved the lives of teens and others from car crashes, and extended life-saving treatment and disease prevention in more than 50 countries.

A graduate of the Columbia University’s College of Physicians and Surgeons and School of Public Health, Dr. Frieden completed infectious diseases training at Yale University and CDC’s Epidemic Intelligence Service. The recipient of numerous awards and honors, Dr. Frieden speaks Spanish and has published more than 200 scientific articles.
The Promise and Progress of Vaccines

Vaccines have changed the world. Viral diseases such as typhoid, polio, smallpox and rubella have cut a deadly swath through human history. The very names of these conditions were for many years the cause of fear and even panic throughout the world, responsible for the suffering and death of untold millions of people as well as the destruction of communities and even civilizations. Because of innovative vaccines, many of these and other once-deadly diseases may, for the first time in history, be controlled or entirely eliminated as a threat to human health.

Improved health and access to basic healthcare—in both the developed and developing world—play a big role in the fight against viral infections. But modern vaccines and their continued development are at the core of the effort to eliminate many of these diseases from human history.

In the developed world, we are witnessing the complete elimination of once deadly threats posed by the smallpox and polio viruses. Other diseases—measles and rubella for instance—are also today essentially preventable and controllable conditions. In short, tens of millions of men, women and children are today living and healthy because they were vaccinated.

Additionally, in the developing world, the threat of many a pandemic disease—like typhoid—has been dramatically reduced and important progress continues to be made in extending the benefit of vaccines and vaccination to a growing portion of the global population.

Certainly, while the practical, current benefit of vaccines and vaccination to public health are manifest, the prospect of additional progress and new benefits from continued vaccine research and development also is exciting. From recent success using vaccination to prevent HPV (human papillomavirus) and reduce the potential of cervical cancer to research into using vaccines to fight HIV/AIDS, pancreatic cancer, malaria and other conditions, vaccines are one key to our ability to confront, manage and eliminate future health challenges.

This is why the 2013 Research & Hope Awards are focusing on vaccines.

The nearly 300 vaccines now in clinical development or under consideration at the Food and Drug Administration (FDA) for patient use are part of a continuum of innovative research and development revolutionizing public health and helping patients around the world avoid numerous deadly diseases.

The promise of vaccines continues to shine brightly. Their role as a critical public health tool is indisputable, and the continuing evolution of new preventative and therapeutic vaccines is indispensable.

Those we honor tonight are dedicated researchers and healthcare providers. Each has played a central role in the creation, testing and use of innovative vaccines. Each makes it possible for new research to continue. Each gives hope to patients the world-over that a now deadly or debilitating disease may be treated, cured or forever prevented.
Every year across the country a new campaign to vaccinate the population against the latest flu strains kicks off in schools, nursing homes, pharmacies, local health clinics and numerous other community venues. Why is it so important?

Think back to the 1918 flu pandemic, when there was no vaccine. Approximately 20%–40% of the worldwide population became ill and an estimated 50 million people died—including nearly 675,000 people in the United States.

The annual effort to develop a new flu vaccine involves extensive collaborative research, testing, planning and logistics.

Each December, PhRMA convenes an open meeting of all stakeholders (including CDC, NIH, FDA, WHO, standards-setting groups and vaccine manufacturers) to identify and address the many potential challenges of producing and distributing the annual flu vaccine. Working together, participants address numerous issues such as strain selection, testing, regulatory issues and production deadlines, as well as standard-setting, technical challenges, lessons learned from prior flu seasons and how to continually improve the process.

The shared goal of the meeting attendees is simple: ensure that the influenza vaccine produced each year meets public health needs to the highest degree possible.

Preventing the potentially devastating human toll of a major flu outbreak requires vigilance, speed, flexibility and adaptability to changing technology. PhRMA’s annual effort bringing together the essential players in the creation, testing, manufacture and distribution of flu vaccines is a catalyst for both readiness and quick action. It helps promote innovative science and medicine by facilitating both understanding and the adoption of new vaccine technologies, and it helps to ensure that healthcare providers and patients have the tools they need to meet the annual influenza challenge.
Academic or Public Research

National Cancer Institute

Douglas R. Lowy, MD

Dr. Lowy received his MD from New York University School of Medicine in 1968. Between 1970 and 1973, he was a research associate in the Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH. He trained in internal medicine at Stanford University and dermatology at Yale University, and started his laboratory at the NCI in 1975. Dr. Lowy previously served as the Deputy Director of the Center for Cancer Research from 1996 to 2011, and as Chief of NCI’s Laboratory of Cellular Oncology since 1983. Dr. Lowy is a member of the National Academy of Sciences (NAS) and also a member of the Institute of Medicine of the NAS. He and his long-term collaborator, John T. Schiller, Ph.D., have received numerous honors, including the 2011 Albert B. Sabin Gold Medal Award and the Federal Employee of the Year Service to America Medal by the Partnership for Public Service.

Dr. Lowy’s laboratory at the NCI Center for Cancer focuses on the molecular biology of tumor viruses and growth regulation.

John T. Schiller, PhD

Dr. Schiller graduated from the University of Wisconsin-Madison with a B.S. in molecular biology in 1975. In 1982, he received a PhD from the Department of Microbiology of the University of Washington in Seattle, and then joined the Laboratory of Cellular Oncology as a National Research Service Award postdoctoral fellow in 1983. Dr. Schiller became a senior staff fellow in the Laboratory of Cellular Oncology in 1986 and a senior investigator in 1992. In 1998, he became chief of the Neoplastic Disease Section of the lab. Along with colleague Douglas Lowy, he has been honored with the Albert B. Sabin Gold Medal Award and the Federal Employee of the Year Service to America Medal by the Partnership for Public Service.

Dr. Schiller’s research has focused on the basic biology and vaccine development for human papillomavirus.

Dr. Douglas R. Lowy and Dr. John T. Schiller are receiving the 2013 Research & Hope Award for Academic or Public Research for the integral role they have played in the development of the human papillomavirus vaccine against cervical cancer, performing fundamental research regarding the nature of the virus, animal studies, and a Phase I trial in humans. Their research directly led to the first HPV vaccine, approved by the FDA in 2006, which has the potential to drastically reduce the incidence of cervical cancer in women.

Today, in addition to their ongoing study of papillomavirus—including the potential use of PV pseudovirus as gene transfer vehicles—Drs. Lowy and Schiller are working with colleagues at the World Health Organization and other organizations to find ways to distribute HPV vaccines to those in need.
Sophie Biernaux, PhD

Dr. Sophie Biernaux serves as Head of the Malaria Vaccine Franchise for GlaxoSmithKline Biologicals where she leads the company’s research and development efforts on malaria vaccines. Dr. Biernaux currently directs all aspects of GSK’s work in advancing the RTS,S malaria vaccine candidate, including the management of the Phase III trials across Africa in conjunction with the company’s Global R&D Department. She also ensures an effective partnership with PATH’s Malaria Vaccine Initiative, GSK’s partner in the study, and a transparent collaboration with European regulatory authorities, the World Health Organization and African governments to accelerate the eventual registration of an effective malaria vaccine.

Dr. Biernaux holds a PhD in cellular biology and immunology and after a couple of years of research at the International Institute of Cellular Pathology in Brussels, she joined SmithKline Beecham in 1986. During more than 10 years, she has led numerous projects and teams, gaining broad experience in all aspects of vaccine development.

Her management competencies have led her to take over the global lead of all pediatric vaccines at GSK, in particular the combined pediatric vaccines and the Neisseria meningitides vaccines. Her deep commitment for the poorest was translated in her heavy involvement in the development of vaccines for the meningitis belt and other vaccines for Africa.

The GlaxoSmithKline Malaria Vaccine Team was selected as the winner of the 2013 PhRMA Research & Hope Award for Biopharmaceutical Industry Research for its longstanding commitment to researching and developing a vaccine against malaria. For almost 30 years, GSK’s Malaria Vaccine Team has devoted tireless effort towards the development of a malaria vaccine, targeted to children in Sub-Saharan Africa.

This team has made significant progress helped by a series of public-private partnerships and strategic collaborations. As a result, they are now in the final stages of a large, multi-center Phase III clinical trial with their malaria vaccine candidate which is anticipated to reach completion in 2014. If successful, the World Health Organization has indicated that a policy recommendation for the vaccine candidate could come as early as 2015. GSK’s malaria vaccine candidate is the most advanced in the world and has the potential to benefit millions of children. If approved, it could be the first ever vaccine developed to help prevent malaria or any disease caused by a parasite.
Linda Fu, MD

The Children’s National Medical Center Vaccine Program is led by Dr. Linda Fu. Dr. Fu is a general pediatrician at Children’s National Medical Center and an Associate Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences. Dr. Fu’s research and advocacy interests focus on reducing barriers to childhood immunizations. She is Principal Investigator of a multi-center behavioral trial comparing the effectiveness of knowledge diffusion strategies for enhancing immunization delivery among a national sample of pediatricians. Dr. Fu also studies the psychosocial reasons for parental vaccine refusal and she recently received funding from the National Institute of Child Health and Human Development at the National Institutes of Health via the K23 mechanism to examine the influences of social networks on normative values regarding HPV vaccination acceptance among parents of early adolescents.

Dr. Fu received an ScB degree from Brown University (1996), MD from the University of California, San Diego (2000), and MS in Clinical Research from Tufts University (2005). She completed her pediatric residency training and a clinic research fellowship at Tufts Medical Center.

The Children’s National Medical Center Vaccine Program, led by Dr. Fu, is receiving the 2013 PhRMA Research & Hope Award for Patient and Community Health for its efforts to increase awareness of the importance of childhood immunization and raise the quality of immunization delivery to an at-risk population in the District of Columbia. These efforts have ensured that a generation of children in our region is protected from a wide range of preventable diseases.

Additionally, ongoing work at the Children’s Research Institute and through the Goldberg Center for Community Pediatric Health exemplifies the continuum of scientific study, clinical practice and stakeholder engagement that PhRMA strives to highlight through the Research & Hope Awards.
American Cancer Society Cancer Action Network (ACS CAN)

www.acscan.org

ACS CAN, the nonprofit, nonpartisan advocacy affiliate of the American Cancer Society, supports evidence-based policy and legislative solutions designed to eliminate cancer as a major health problem. ACS CAN works to encourage elected officials and candidates to make cancer a top national priority. ACS CAN gives ordinary people extraordinary power to fight cancer with the training and tools they need to make their voices heard. For more information, visit www.acscan.org.

American Nurses Association (ANA)

www.nursingworld.org

ANA is the only full-service professional organization representing the interests of the nation’s 3.1 million registered nurses through its constituent and state nurses associations and its organizational affiliates. ANA advances the nursing profession by fostering high standards of nursing practice, promoting the rights of nurses in the workplace, projecting a positive and realistic view of nursing, and by lobbying the Congress and regulatory agencies on health care issues affecting nurses and the public.

American Osteopathic Association (AOA)

www.osteopathic.org

The American Osteopathic Association (AOA) proudly represents its professional family of more than 104,000 osteopathic physicians (DOs) and osteopathic medical students; promotes public health; encourages scientific research; serves as the primary certifying body for DOs; is the accrediting agency for osteopathic medical schools; and has federal authority to accredit hospitals and other health care facilities. More information on DOs/osteopathic medicine can be found at www.osteopathic.org.

National Association of School Nurses (NASN)

www.nASN.org

The National Association of School Nurses (NASN) is a non-profit specialty nursing organization, incorporated in 1979, which represents school nurses exclusively. NASN has 15,000 members and 49 affiliates, including the District of Columbia and overseas. NASN advances the specialty practice of school nursing to improve the health and academic success of all students.
BioCentury Publications
www.biocentury.com
BioCentury Publications, Inc. is recognized as the leading provider of value-added information, analysis and data essential to the development and sustainability of life science ventures.

Pharmaceutical Executive
www.pharmexec.com
PHARMACEUTICAL EXECUTIVE covers the intersection between strategy and policy globally. We provide pharma executives with information and new ideas on strategy, regulation, marketing, finance, IT and R&D. PHARMACEUTICAL EXECUTIVE audience is over 175,000 pharmaceutical executives worldwide.

pharmaphorum
www.pharmaphorum.com
pharmaphorum media provides digital content marketing and communications solutions for the pharmaceutical sector, supported by the industry leading channel www.pharmaphorum.com, a digital podium for thought leadership and innovation within healthcare.

“The Pink Sheet”
“The Pink Sheet” delivers expert, in-depth analysis of regulatory, legislative, legal and business developments—and their bottom-line impact on the industry. Its comprehensive coverage is vital for successful business development and commercialization strategies that drive profits.

SCRIP Intelligence
www.scripinelligence.com
SCRIP Intelligence—vital pharmaceutical industry ideas and global signals for your career, your business and your future.

SCRIP Intelligence subscribers receive a glimpse of the future from the daily drumbeat of crucial events across the sector spectrum—from biotech start-ups to multinational giants; research boutiques to generic manufacturers; and suppliers large and small.

Experienced writers and analysts are based in key geographic markets to convey all aspects of the industry. Global hot topics such as orphan diseases, personalized medicine, and management strategies from developed to emerging markets are covered with local depth and insight.

WUSA 9
www.wusa9.com
WUSA 9 is part of Gannett Co., Inc., a leading international news and information company that publishes 101 daily newspapers in the US, including USA TODAY, the nation’s largest selling daily newspaper. The company also owns more than 750 non-daily publications in the US, and USA WEEKEND, a weekly newspaper magazine. Gannett also operates 23 television stations in the United States, and is an internet leader with its TV stations and newspaper websites, including USA TODAY.com, one of the most popular news sites on the web.

The one constant throughout WUSA 9’s 55-plus years of history in Washington has been WUSA’s commitment to serve the local community. One way WUSA 9 serves our local community is through regular health reporting. WUSA 9 is currently working with FORCE—Facing Our Risk of Cancer Empowered on a campaign to raise awareness of the hereditary risk of breast cancer. WUSA has also launched an Affordable Health Care education campaign to inform viewers of the expected changes in healthcare in the months ahead. WUSA 9 also supports the Leukemia/Lymphoma Society, the American Heart Association, and other organizations through our comprehensive media partnerships.
271 vaccines in development

- Allergy: 15
- Cancer: 99
- Infectious diseases: 137
- Neurological disorders: 10
- Other: 13

Source: PhRMA 2009 Vaccines in Development